Medicaid Pharmacy and Therapeutics Committee Agenda for June 11, 2010
The Pharmacy & Therapeutics (P&T) Committee will meet June 11, 2010, from 8:30 a.m. to 4:30 p.m., Meeting Room 6, Concourse, Empire State Plaza, Albany, New York
A. Preferred Drug Program: Initial Review
Description: The Committee will review the following therapeutic classes for Preferred Drug Program inclusion and recommend preferred and non-preferred status.
1. Platelet Inhibitors
Drugs Affected: Aggrenox (dipyridamole ER/aspirin), dipyridamole, Effient (prasugrel), Persantine (dipyridamole), Plavix (clopidogrel), ticlopidine
2. Ophthalmic Beta Blockers
Drugs Affected: Betagan (levobunolol HCl), betaxolol HCl, Betimol (timolol), Betoptic S (betaxolol HCl), carteolol HCl, Combigan (brimonidine tartrate/ timolol maleate), Istalol (timolol maleate), levobunolol HCl, metipranolol, Optipranolol (metipranolol), timolol maleate, Timoptic (timolol maleate), Timoptic Ocudose (timolol maleate preservative free), Timoptic-XE (timolol maleate gel)
B. Preferred Drug Program: Re-review
Description: The Committee will re-review each therapeutic class subject to the Preferred Drug Program periodically as described and listed below.
- The Committee will review new clinical and financial information as required, to recommend preferred and non-preferred drugs.*
- The Committee will only consider clinical information which is new since the previous review of the therapeutic class and then consider financial information.
- New clinical information may include a new drug or drug product information, new indications, new safety information or new published comparative clinical trials (placebo-only controlled studies, information in abstract form alone, posters, and unpublished data is poor quality evidence for the purpose of re-review and submission is discouraged).
- Those wishing to submit new clinical information must do so in an electronic format by May 28, 2010 or the Committee may not have ample time to review the information.
*The current preferred and non-preferred status of drugs subject to the Preferred Drug List (PDL) may be viewed at https://newyork.fhsc.com/downloads/providers/NYRx_PDP_PDL.pdf
No relevant new clinical information was found for the therapeutic classes listed below (items 1 - 3). Any new clinical information must be submitted to the Department by May 28, 2010. The Committee is only interested in clinical information that is new since the previous review.
1. Ophthalmic Alpha-2 Adrenergic Agonists (previous review date June 10, 2009)
Drugs Affected: Alphagan P (brimonidine), apraclonidine, brimonidine, Iopidine (apraclonidine)
2. Ophthalmic Prostaglandin Agonists (previous review date June 10, 2009)
Drugs Affected: Lumigan (bimatoprost), Travatan (travoprost), Travatan Z (travoprost), Xalatan (latanoprost)
3. Topical Anti-Virals (previous review date February 26, 2009)
Drugs Affected: Abreva (docosanol), Denavir (penciclovir), Zovirax (acyclovir)
New information is known to exist for the therapeutics classes listed below (items 4 - 13). The Committee will evaluate the following therapeutic classes to determine the significance of the new information on preferred and non-preferred status.
4. Multiple Sclerosis Agents (previous review date September 11, 2009)
Drugs Affected: Avonex (interferon beta-1a), Betaseron (interferon beta-1b), Copaxone (glatiramer acetate), Extavia (interferon beta-1b), Rebif (interferon beta-1a)
5. Non-Ergot Dopamine Receptor Agonists (previous review date February 26, 2009)
Drugs Affected: Mirapex (pramipexole), Mirapex ER (pramipexole ER), pramipexole, Requip (ropinirole), Requip XL (ropinirole ER), ropinirole
6. Ophthalmic Antihistamines (previous review date June 10, 2009)
Drugs Affected: azelastine, Bepreve (bepotastine), Elestat (epinastine), Emadine (emedastine), Optivar (azelastine), Patanol (olopatadine), Pataday (olopatadine)
7. Ophthalmic NSAIDs (previous review date June 10, 2009)
Drugs Affected: Acular (ketorolac), Acular LS (ketorolac), Acular PF (ketorolac), Acuvail (ketorolac tromethamine), diclofenac, flurbiprofen, ketorolac, Nevanac (nepafenac), Ocufen (flurbiprofen), Voltaren (diclofenac), Xibrom (bromfenac)
8. Ophthalmic Fluoroquinolones (previous review date June 10, 2009)
Drugs Affected: Besivance (besifloxacin), Ciloxan (ciprofloxacin), ciprofloxacin, IQUIX (levofloxacin), Ocuflox (ofloxacin), ofloxacin, Quixin (levofloxacin), Vigamox (moxifloxacin), Zymar (gatifloxacin)
9. Topical Antibiotics (previous review date February 26, 2009)
Drugs Affected: Altabax (retapamulin), Bactroban (mupirocin), Centany (mupirocin), mupirocin
10. Topical Agents for Psoriasis (previous review date February 26, 2009)
Drugs Affected: calcipotriene, Dovonex (calcipotriene), Taclonex (calcipotriene/betamethasone dipropionate), Vectical (calcitriol)
11. Oral Antihistamines (previous review date June 10, 2009)
Drugs Affected: Allegra/Allegra-D (fexofenadine/fexofenadine PSE), cetirizine/cetirizine-D OTC, Clarinex/Clarinex-D (desloratadine/desloratadine PSE), fexofenadine, fexofenadine-D, loratadine/loratadine D OTC, Semprex-D (acrivastine/PSE), Xyzal (levocetirizine)
12. Nasal Antihistamines (previous review date February 26, 2009)
Drugs Affected: Astelin (azelastine), Astepro (azelastine), Patanase (olopatadine)
13. Nasal Corticosteroids (previous review date June 10, 2009)
Drugs Affected: Beconase AQ (beclomethasone dipropionate), Flonase (fluticasone propionate), flunisolide, fluticasone propionate, Nasacort AQ (triamcinolone acetonide), Nasonex (mometasone furoate), Omnaris (ciclesonide), Rhinocort Aqua (budesonide), Veramyst (fluticasone furoate)
Agenda Timeline (subject to change based on meeting proceedings)
|8:30 - 8:45||Welcome and Introductions|
|8:45 - 10:15||Public Comment Period|
|10:15 - 10:30||Break|
|10:30 - 12:30||PDP review of Platelet Inhibitors and Ophthalmic Beta Blockers
PDP re-review of Ophthalmic Alpha-2 Adrenergic Agonists, Ophthalmic Prostaglandin Agonists, Topical Anti-Virals, Multiple Sclerosis Agents, Non-Ergot Dopamine Receptor Agonists
|12:30 - 1:30||Lunch Break/Executive Session (evaluation of confidential supplemental rebate information)|
|1:30 - 1:45||Summary of Recommendations|
|1:45 - 3:00||PDP re-review Ophthalmic Antihistamines, Ophthalmic NSAIDs, Ophthalmic Fluoroquinolones, Topical Antibiotics, Topical Agents for Psoriasis, Oral Antihistamines, Nasal Antihistamines, Nasal Corticosteroids|
|3:00 - 3:30||Break/Executive Session (evaluation of confidential supplemental rebate information)|
|3:30 - 3:45||Summary of Recommendations|
|3:45 - 4:30||Final Comments and Adjournment|
- Interested parties must notify DOH by June 3, 2010 of their request to address the Committee during the public comment period. Requests may be made by calling 518-486-3209 or e-mailing email@example.com (please reference P&T Committee). Please note this is a new mailbox.
- Public comments are limited to therapeutic classes on the agenda and new clinical information for the PDP classes being re-reviewed. Comments must be brief (2 minutes) and the total comment period will not exceed 90 minutes.
- All written statements must be received in an electronic format by June 3, 2010. Written statements should summarize key points and may not exceed two (2) pages in length.
- Any studies cited should be referenced, with the primary source of funding included.
- Clinical information must be submitted in an electronic format by May 28, 2010 or the Committee may not have ample time to review the information. For the therapeutic classes subject to the PDP re-review, submitted clinical information must be new since the previous review of the therapeutic class.